Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 195

1.

An exploratory study of social problems experienced by ambulatory cancer patients in Japan: Frequency and association with perceived need for help.

Hisamura K, Matsushima E, Tsukayama S, Murakami S, Motoo Y.

Psychooncology. 2018 Mar 12. doi: 10.1002/pon.4703. [Epub ahead of print]

PMID:
29528536
2.

[Long-Term Survival Due to Combination Therapy in a Patient with Locally Advanced Body-Tail Pancreatic Cancer].

Ueda N, Fujii Y, Miura S, Fujita J, Tomita Y, Ohnishi T, Fujita H, Kinami S, Omote K, Nakano Y, Kosaka T, Motoo Y.

Gan To Kagaku Ryoho. 2017 Nov;44(12):1373-1375. Japanese.

PMID:
29394638
3.

Ramucirumab Plus Paclitaxel: A Possible New Chemotherapy Regimen for Neuroendocrine Carcinoma of the Stomach.

Motoo Y.

Intern Med. 2018 Mar 1;57(5):631-632. doi: 10.2169/internalmedicine.9709-17. Epub 2017 Nov 20. No abstract available.

4.

In vivo imaging xenograft models for the evaluation of anti-brain tumor efficacy of targeted drugs.

Kita K, Arai S, Nishiyama A, Taniguchi H, Fukuda K, Wang R, Yamada T, Takeuchi S, Tange S, Tajima A, Nakada M, Yasumoto K, Motoo Y, Murakami T, Yano S.

Cancer Med. 2017 Dec;6(12):2972-2983. doi: 10.1002/cam4.1255. Epub 2017 Nov 10.

5.

Evaluation of the Predictive Validity of Thermography in Identifying Extravasation With Intravenous Chemotherapy Infusions.

Matsui Y, Murayama R, Tanabe H, Oe M, Motoo Y, Wagatsuma T, Michibuchi M, Kinoshita S, Sakai K, Konya C, Sugama J, Sanada H.

J Infus Nurs. 2017 Nov/Dec;40(6):367-374. doi: 10.1097/NAN.0000000000000250.

6.

[Clinical Study on the Efficacy and Continuous Docetaxel Based Chemotherapy Treatment for Castration-Resistant Prostate Cancer].

Chikazawa I, Inoue S, Nakazawa Y, Nakai D, Morita N, Tanaka T, Motoo Y, Miyazawa K.

Hinyokika Kiyo. 2017 Sep;63(9):351-357. doi: 10.14989/ActaUrolJap_63_9_351. Japanese.

PMID:
28992664
7.

Effect of ninjin'yoeito and ginseng extracts on oxaliplatin-induced neuropathies in mice.

Suzuki T, Yamamoto A, Ohsawa M, Motoo Y, Mizukami H, Makino T.

J Nat Med. 2017 Oct;71(4):757-764. doi: 10.1007/s11418-017-1113-6. Epub 2017 Jul 10.

PMID:
28695397
8.

Standards of Reporting Kampo Products (STORK) in research articles.

Motoo Y, Hakamatsuka T, Kawahara N, Arai I, Tsutani K.

J Integr Med. 2017 May;15(3):182-185. doi: 10.1016/S2095-4964(17)60347-9.

PMID:
28494848
9.
10.

Ninjin'yoeito and ginseng extract prevent oxaliplatin-induced neurodegeneration in PC12 cells.

Suzuki T, Yamamoto A, Ohsawa M, Motoo Y, Mizukami H, Makino T.

J Nat Med. 2015 Oct;69(4):531-7. doi: 10.1007/s11418-015-0921-9. Epub 2015 May 27.

PMID:
26014046
11.

[Gender difference in clinical practice for cancer patients].

Motoo Y.

Nihon Rinsho. 2015 Apr;73(4):666-70. Japanese.

PMID:
25936159
12.

Description of Kampo medicines in the clinical practice guidelines for irritable bowel syndrome.

Motoo Y.

J Gastroenterol. 2015 Jul;50(7):816. doi: 10.1007/s00535-015-1075-y. Epub 2015 Apr 23. No abstract available.

PMID:
25900215
13.

[Patient education for side effects of anti-cancer agents].

Motoo Y.

Nihon Rinsho. 2015 Feb;73 Suppl 2:98-101. Japanese. No abstract available.

PMID:
25831731
14.

Effect of Saikokeishito, a Kampo medicine, on hydrogen peroxide-induced premature senescence of normal human dermal fibroblasts.

Takata T, Motoo Y, Tomosugi N.

J Integr Med. 2014 Nov;12(6):495-503. doi: 10.1016/S2095-4964(14)60052-2.

PMID:
25412667
15.

Acupuncture and herbal medicine for cancer patients 2014.

Efferth T, Lee S, Motoo Y, Schröder S.

Evid Based Complement Alternat Med. 2014;2014:326179. doi: 10.1155/2014/326179. Epub 2014 Aug 28. No abstract available.

16.

Use of Kampo diagnosis in randomized controlled trials of Kampo products in Japan: a systematic review.

Motoo Y, Arai I, Tsutani K.

PLoS One. 2014 Aug 13;9(8):e104422. doi: 10.1371/journal.pone.0104422. eCollection 2014. Review.

17.

Acupuncture and herbal medicine for cancer patients.

Schröder S, Lee S, Efferth T, Motoo Y.

Evid Based Complement Alternat Med. 2013;2013:313751. doi: 10.1155/2013/313751. Epub 2013 Nov 25. No abstract available.

18.

Role of Kampo medicine in integrative cancer therapy.

Yamakawa J, Motoo Y, Moriya J, Ogawa M, Uenishi H, Akazawa S, Sasagawa T, Nishio M, Kobayashi J.

Evid Based Complement Alternat Med. 2013;2013:570848. doi: 10.1155/2013/570848. Epub 2013 Aug 22.

19.

Significance of Kampo, traditional Japanese medicine, in supportive care of cancer patients.

Yamakawa J, Motoo Y, Moriya J, Ogawa M, Uenishi H, Akazawa S, Sasagawa T, Nishio M, Kobayashi J.

Evid Based Complement Alternat Med. 2013;2013:746486. doi: 10.1155/2013/746486. Epub 2013 Jun 19.

20.

Significance of Kampo, Japanese traditional medicine, in the treatment of obesity: basic and clinical evidence.

Yamakawa J, Moriya J, Takeuchi K, Nakatou M, Motoo Y, Kobayashi J.

Evid Based Complement Alternat Med. 2013;2013:943075. doi: 10.1155/2013/943075. Epub 2013 Apr 15.

21.

[Revision of the training curriculum of Japan Society of Gastroenterology: biliary tract and pancreas].

Motoo Y, Hirooka Y, Shimizu K, Isayama H, Yoshidome H.

Nihon Shokakibyo Gakkai Zasshi. 2013 May;110(5):820-4. Japanese. No abstract available.

PMID:
23648537
22.

[Revision of the training curriculum of Japan Society of Gastroenterology].

Ishibashi H, Takikawa H, Nakao A, Watanabe M, Niwa Y, Nakamura T, Hokari R, Fukuzawa Y, Motoo Y, Morizane T, Sugano K.

Nihon Shokakibyo Gakkai Zasshi. 2013 May;110(5):788-95. Japanese. No abstract available.

PMID:
23648532
23.

Aberrant glycogen synthase kinase 3β is involved in pancreatic cancer cell invasion and resistance to therapy.

Kitano A, Shimasaki T, Chikano Y, Nakada M, Hirose M, Higashi T, Ishigaki Y, Endo Y, Takino T, Sato H, Sai Y, Miyamoto K, Motoo Y, Kawakami K, Minamoto T.

PLoS One. 2013;8(2):e55289. doi: 10.1371/journal.pone.0055289. Epub 2013 Feb 8.

24.

Meaning of tumor protein 53-induced nuclear protein 1 in the molecular mechanism of gemcitabine sensitivity.

Nakaya N, Ishigaki Y, Nakajima H, Murakami M, Shimasaki T, Takata T, Ozaki M, Dusetti NJ, Iovanna JL, Motoo Y.

Mol Clin Oncol. 2013 Jan;1(1):100-104. Epub 2012 Aug 8.

25.

Aberrant glycogen synthase kinase 3β in the development of pancreatic cancer.

Shimasaki T, Kitano A, Motoo Y, Minamoto T.

J Carcinog. 2012;11:15. doi: 10.4103/1477-3163.100866. Epub 2012 Sep 13.

26.

Daily 500 mg valacyclovir is effective for prevention of Varicella zoster virus reactivation in patients with multiple myeloma treated with bortezomib.

Fukushima T, Sato T, Nakamura T, Iwao H, Nakajima A, Miki M, Sakai T, Kawanami T, Sawaki T, Fujita Y, Tanaka M, Masaki Y, Okazaki T, Nakajima H, Motoo Y, Umehara H.

Anticancer Res. 2012 Dec;32(12):5437-40.

PMID:
23225448
27.

Characterization of proteins secreted by pancreatic cancer cells with anticancer drug treatment in vitro.

Takata T, Ishigaki Y, Shimasaki T, Tsuchida H, Motoo Y, Hayashi A, Tomosugi N.

Oncol Rep. 2012 Dec;28(6):1968-76. doi: 10.3892/or.2012.2020. Epub 2012 Sep 5.

28.

Loss of HITS (FAM107B) expression in cancers of multiple organs: tissue microarray analysis.

Nakajima H, Koizumi K, Tanaka T, Ishigaki Y, Yoshitake Y, Yonekura H, Sakuma T, Fukushima T, Umehara H, Ueno S, Minamoto T, Motoo Y.

Int J Oncol. 2012 Oct;41(4):1347-57. doi: 10.3892/ijo.2012.1550. Epub 2012 Jul 10.

PMID:
22825356
29.

Prediction of docetaxel monotherapy-induced neutropenia based on the monocyte percentage.

Sato I, Nakaya N, Shimasaki T, Nakajima H, Motoo Y.

Oncol Lett. 2012 Apr 1;3(4):860-864. Epub 2012 Jan 9.

30.

Glycogen synthase kinase 3β inhibition sensitizes pancreatic cancer cells to gemcitabine.

Shimasaki T, Ishigaki Y, Nakamura Y, Takata T, Nakaya N, Nakajima H, Sato I, Zhao X, Kitano A, Kawakami K, Tanaka T, Takegami T, Tomosugi N, Minamoto T, Motoo Y.

J Gastroenterol. 2012 Mar;47(3):321-33. doi: 10.1007/s00535-011-0484-9. Epub 2011 Nov 1.

PMID:
22041920
31.

[A case of primary cardiac angiosarcoma associated with cardiac tamponade].

Nakaya N, Sato I, Shimasaki T, Nakajima H, Kurose N, Nojima T, Motoo Y.

Gan To Kagaku Ryoho. 2011 Aug;38(8):1353-5. Japanese.

PMID:
21829080
32.

Efficacy and safety of bortezomib plus dexamethasone therapy for refractory or relapsed multiple myeloma: once-weekly administration of bortezomib may reduce the incidence of gastrointestinal adverse events.

Fukushima T, Nakamura T, Iwao H, Nakajima A, Miki M, Sato T, Sakai T, Sawaki T, Fujita Y, Tanaka M, Masaki Y, Nakajima H, Motoo Y, Umehara H.

Anticancer Res. 2011 Jun;31(6):2297-302.

PMID:
21737655
33.

[Combination chemotherapy of docetaxel and UFT against hormone refractory prostate cancer].

Shimasaki T, Miyazawa K, Moriyama M, Tanaka T, Sato I, Nakaya N, Nakajima H, Kubo A, Suzuki K, Motoo Y.

Hinyokika Kiyo. 2011 Mar;57(3):163-6. Japanese.

34.

[Chemotherapy for urological cancer : usefulness and feasibility of current protocols].

Hara I, Motoo Y.

Hinyokika Kiyo. 2011 Mar;57(3):151-2. Japanese.

35.

Scanning electron microscopy with an ionic liquid reveals the loss of mitotic protrusions of cells during the epithelial-mesenchymal transition.

Ishigaki Y, Nakamura Y, Takehara T, Shimasaki T, Tatsuno T, Takano F, Ueda Y, Motoo Y, Takegami T, Nakagawa H, Kuwabata S, Nemoto N, Tomosugi N, Miyazawa S.

Microsc Res Tech. 2011 Nov;74(11):1024-31. doi: 10.1002/jemt.20989. Epub 2011 Mar 16.

PMID:
21413103
36.

Traditional Japanese medicine, Kampo: its history and current status.

Motoo Y, Seki T, Tsutani K.

Chin J Integr Med. 2011 Feb;17(2):85-7. doi: 10.1007/s11655-011-0653-y. Epub 2011 Feb 10. Review.

PMID:
21390572
37.

Cost-effectiveness analysis of KRAS testing and cetuximab as last-line therapy for colorectal cancer.

Shiroiwa T, Motoo Y, Tsutani K.

Mol Diagn Ther. 2010 Dec 1;14(6):375-84. doi: 10.2165/11587610-000000000-00000.

PMID:
21275455
38.

Metabolic disorder, inflammation, and deregulated molecular pathways converging in pancreatic cancer development: implications for new therapeutic strategies.

Motoo Y, Shimasaki T, Ishigaki Y, Nakajima H, Kawakami K, Minamoto T.

Cancers (Basel). 2011 Jan 24;3(1):446-60. doi: 10.3390/cancers3010446.

39.

Multiple factors influencing the release of hTERT mRNA from pancreatic cancer cell lines in in vitro culture.

Okada G, Watanabe H, Ohtsubo K, Mouri H, Yamaguchi Y, Motoo Y, Sawabu N.

Cell Biol Int. 2012 Jun 1;36(6):545-53. doi: 10.1042/CBI20090471. Erratum in: Cell Biol Int. 2012 Jul;36(7):689-90.

PMID:
21080909
40.

[DU-PAN-2, SPan-1].

Motoo Y.

Nihon Rinsho. 2010 Jul;68 Suppl 7:732-5. Japanese. No abstract available.

PMID:
20960859
41.

Epithelial-to-mesenchymal transition in pancreatic adenocarcinoma.

Cano CE, Motoo Y, Iovanna JL.

ScientificWorldJournal. 2010 Oct 1;10:1947-57. doi: 10.1100/tsw.2010.183. Review.

42.

Human SMG-1 is involved in gemcitabine-induced primary microRNA-155/BIC up-regulation in human pancreatic cancer PANC-1 cells.

Xia QS, Ishigaki Y, Zhao X, Shimasaki T, Nakajima H, Nakagawa H, Takegami T, Chen ZH, Motoo Y.

Pancreas. 2011 Jan;40(1):55-60. doi: 10.1097/MPA.0b013e3181e89f74.

PMID:
20871480
43.

Induction of HITS, a newly identified family with sequence similarity 107 protein (FAM107B), in cancer cells by heat shock stimulation.

Nakajima H, Ishigaki Y, Xia QS, Ikeda T, Yoshitake Y, Yonekura H, Nojima T, Tanaka T, Umehara H, Tomosugi N, Takata T, Shimasaki T, Nakaya N, Sato I, Kawakami K, Koizumi K, Minamoto T, Motoo Y.

Int J Oncol. 2010 Sep;37(3):583-93.

PMID:
20664927
44.

[Curatively resected case of non-functioning pancreatic neuroendocrine carcinoma with multiple liver metastases after downstaging with S-1 monotherapy].

Sato I, Ueda N, Kinoshita E, Minato H, Ohno K, Nakaya N, Shimasaki T, Nakajima H, Kosaka T, Motoo Y.

Gan To Kagaku Ryoho. 2010 Jul;37(7):1341-4. Japanese.

PMID:
20647723
45.

[Effect of anti-cancer drugs on the expression of BIC/miR-155 in human pancreatic cancer PANC-1 cells].

Xia QS, Ishigaki Y, Sun L, Chen R, Motoo Y.

Zhonghua Yi Xue Za Zhi. 2010 Jan 12;90(2):123-7. Chinese.

PMID:
20356498
46.

The combination of baicalin and baicalein enhances apoptosis via the ERK/p38 MAPK pathway in human breast cancer cells.

Zhou QM, Wang S, Zhang H, Lu YY, Wang XF, Motoo Y, Su SB.

Acta Pharmacol Sin. 2009 Dec;30(12):1648-58. doi: 10.1038/aps.2009.166.

47.

Dietary tea catechins increase fecal energy in rats.

Unno T, Osada C, Motoo Y, Suzuki Y, Kobayashi M, Nozawa A.

J Nutr Sci Vitaminol (Tokyo). 2009;55(5):447-51.

48.

An emerging strategy for cancer treatment targeting aberrant glycogen synthase kinase 3 beta.

Miyashita K, Nakada M, Shakoori A, Ishigaki Y, Shimasaki T, Motoo Y, Kawakami K, Minamoto T.

Anticancer Agents Med Chem. 2009 Dec;9(10):1114-22. Review.

PMID:
19925395
49.

Deregulated GSK3{beta} sustains gastrointestinal cancer cells survival by modulating human telomerase reverse transcriptase and telomerase.

Mai W, Kawakami K, Shakoori A, Kyo S, Miyashita K, Yokoi K, Jin M, Shimasaki T, Motoo Y, Minamoto T.

Clin Cancer Res. 2009 Nov 15;15(22):6810-9. doi: 10.1158/1078-0432.CCR-09-0973. Epub 2009 Nov 10.

50.

Advanced hepatocellular carcinoma treated effectively with irinotecan via hepatic arterial infusion followed by proton beam therapy.

Ohtsubo K, Watanabe H, Tsuchiyama T, Mouri H, Yamaguchi Y, Motoo Y, Okai T, Sanada J, Matsui O, Kitamura T, Fujiki R, Tokuuye K, Sawabu N.

J Infect Chemother. 2009 Oct;15(5):316-21. doi: 10.1007/s10156-009-0702-z. Epub 2009 Oct 24.

PMID:
19856070

Supplemental Content

Support Center